Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › resmetirom

resmetirom

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Novel pharmacotherapies like resmetirom and GLP-1 receptor agonists offer potential concurrent hepatic and cardiovascular benefits
Cardiology Sys. Review
Novel pharmacotherapies like resmetirom and GLP-1 receptor agonists offer potential concurrent hepatic and cardiovascular benefits New Medications Show Potential to Treat Liver and Heart Disease
This systematic review examines the epidemiological links and shared pathophysiological mechanisms between metabolic dysfunction-associated …
Newer drugs like resmetirom and GLP-1 receptor agonists may offer dual benefits for patients with both liver and heart conditions.
Frontiers Jul 27, 2026
Network meta-analysis finds pegozafermin, OCA, and resmetirom outperform placebo for MASLD fibrosis improvement
Gastroenterology Meta-analysis
Network meta-analysis finds pegozafermin, OCA, and resmetirom outperform placebo for MASLD fibrosis improvement New Liver Treatments Show Real Promise in Reversing Scarring
A systematic review and network meta-analysis of 10,119 adult patients with MASLD found pegozafermin, obeticholic acid (OCA), and resmetirom…
For the first time, doctors have clear evidence that new medications can help reverse the dangerous liver scarring caused by common fatty li…
Apr 10, 2026